Humans have been affected by the blood sugar issues for hundreds of years, and diabetes new medicine has been a priority in cultures around the world. The first known description of diabetes symptoms was discovered on Egyptian papyrus that dates back to 1552 B.C. By 1674, English Physician Thomas Willis coined the term diabetes mellitus to describe the sweetness of diabetic urine. It was a pair of Canadian scientists named Frederick Banting and Charles Best who discovered insulin in 1921. The next year, the first insulin injection was given to a 14-year-old boy who was dying of diabetes. This was a milestone in medical history, and the search for diabetes new medicine has never slowed down since.
In 1982, the FDA approved an insulin injection called Humulin N, a replication of the human insulin hormone. More than a decade later, oral diabetes medicine Glucophage hit the market and was targeted for those with non-insulin dependent diabetes. Bayer’s Precose is a drug that was approved by the FDA in the mid-1990s. It acts as a glucosidase inhibitor that slows down the enzyme that turns carbohydrates in to glucose, ultimately lowering blood sugar levels after a person consumes their next meal. Since then Bayer has developed several diabetes combatants.
Search For Diabetes New Medicine Still Going Strong
In China, diabetes rates are constantly increasing, so diabetes new medicine is always in demand. Bayer is a company that has been on the forefront of diabetes new medicine, and their generic-brand product Glucobay is popular in China. However, there is a large desire in the country to make new developments, and they have the potential to become a major competitor with Bayer in the future. It is predicted that newer classes of drugs will be the most rapidly growing diabetes new medicines in China. Sanofi, a French drugmaker, is also offering staunch competition with its introduction of Lantus insulin nearly eight years ago.
Recently, medical device makers have upped the anti by focusing on creating an artificial pancreas that would be beneficial to people with type 1 diabetes. The machine would consist of a complicated system of sensors and pumps that could be worn outside the body. A device of this nature goes a step beyond diabetes new medicine.
A few new diabetes medicines have recently hit the market. Gliptin, an oral drug, treats type 2 diabetes and has provided an ability to regenerate the pancreas in mice. A study in humans has not been conducted yet, but if they experience the same results as mice the breakthrough would be a very significant one. GLP-1 is a new diabetes injection medicine that can cause weight loss in patients. SGLT-2 inhibitors are likely to emerge on the Indian market in 2012, and they are supposed to stop the kidneys from reabsorbing glucose.
